
<mods xmlns="http://www.loc.gov/mods/v3" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-4.xsd">
    
    <titleInfo>
        <title>Development and characterization of a long‐acting recombinant hFSH agonist</title>
    </titleInfo>
    <name type="personal">
        <namePart type="family">Klein</namePart>
        <namePart type="given">Joshua U.</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Obstetrics and Gynecology</affiliation>
    </name>
    <name type="personal">
        <namePart type="family">Lobel</namePart>
        <namePart type="given">Leslie I.</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Obstetrics and Gynecology</affiliation>
    </name>
    <name type="personal" ID="svp1">
        <namePart type="family">Pollack</namePart>
        <namePart type="given">Susan V.</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Obstetrics and Gynecology</affiliation>
    </name>
    <name type="personal">
        <namePart type="family">Lustbader</namePart>
        <namePart type="given">Brandie</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
    </name>
    <name type="personal" ID="to166">
        <namePart type="family">Ogden</namePart>
        <namePart type="given">Robert T.</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Biostatistics</affiliation>
    </name>
    <name type="personal" ID="mvs9">
        <namePart type="family">Sauer</namePart>
        <namePart type="given">Mark V.</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Obstetrics and Gynecology</affiliation>
    </name>
    <name type="personal" ID="jwl2">
        <namePart type="family">Lustbader</namePart>
        <namePart type="given">Joyce W.</namePart>
        <role>
            <roleTerm type="text">author</roleTerm>
        </role>
        <affiliation>Columbia University. Obstetrics and Gynecology</affiliation>
    </name>
    <name type="corporate">
        <namePart>Columbia University. Obstetrics and Gynecology</namePart>
        <role>
            <roleTerm type="text">originator</roleTerm>
        </role>
    </name>
    <typeOfResource>text</typeOfResource>
    <genre>Articles</genre>
    
    <originInfo>
        <dateIssued encoding="w3cdtf" keyDate="yes">2003</dateIssued>
    </originInfo>
    
    <language>
        <languageTerm type="text">English</languageTerm>
    </language>
    <abstract>Background: Fusion of the carboxyterminal peptide (CTP) of hCG to FSH results in a follitropin agonist with an extended half-life, presumably due to the four O-oligosaccharides on the CTP. Alternatively, an rhFSH analogue containing additional N-linked carbohydrate is described in this report. Methods: A DNA sequence containing two N-oligosaccharide signal sequences was ligated into a vector containing hFSHβ- and α-subunit encoding cDNA, and expressed in CHO-K1 cells. In-vitro bioactivity of the single-chain hormone was assessed in CHO cells expressing the hFSH receptor. Pharmacokinetic values were derived from serial serum assays of the analogue in immature female rats following a single i.v. injection. In-vivo bioactivity was assessed by measuring ovarian weight gain 3 days post-injection. Results: rhFSH-N2 and native rhFSH induced comparable levels of cAMP in vitro. t1/2 for native rhFSH, rhFSH-CTP and rhFSH-N2 were 3.7, 7.1 and 7.3 h respectively. Rats receiving rhFSH-N2 had a mean ± SD ovarian weight 3 days post-i.v. injection (22 ± 3.6 mg) significantly greater than rats receiving rhFSH and saline (16.7 ± 1.5 and 15.3 ± 0.47 mg respectively, P &lt; 0.05). Conclusions: rhFSH-N2 has prolonged half-life and increased bioactivity compared with native rhFSH. This rhFSH agonist, and other analogues containing additional N-oligosaccharides may have important clinical applications.</abstract>
    <subject>
        <topic>Obstetrics and gynecology</topic>
    </subject>
    <subject>
        <topic>Pharmacology</topic>
    </subject>
    <relatedItem type="host">
        <titleInfo>
            <title>Human Reproduction</title>
        </titleInfo>
        <part>
            <detail type="volume">
                <number>18</number>
            </detail>
            <detail type="issue">
                <number>1</number>
            </detail>
            <extent unit="page">
                <start>50</start>
                <end>56</end>
            </extent>
            <date>2003-01</date>
        </part>
        <identifier type="doi">http://dx.doi.org/10.1093/humrep/deg024</identifier>
    </relatedItem>
    <identifier type="hdl">http://hdl.handle.net/10022/AC:P:14414</identifier>
    
    <location>
        <physicalLocation authority="marcorg">NNC</physicalLocation>
    </location>
    
    <recordInfo>
        <recordContentSource authority="marcorg">NNC</recordContentSource>
        <recordCreationDate encoding="w3cdtf">2012-08-16 15:12:37 -0400</recordCreationDate>
        <recordChangeDate encoding="w3cdtf">2012-08-16 15:44:25 -0400</recordChangeDate>
        <recordIdentifier>8434</recordIdentifier>
        <languageOfCataloging>
            <languageTerm authority="iso639-2b">eng</languageTerm>
        </languageOfCataloging>
    </recordInfo>
    
</mods>
